Stay updated on Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedA new revision label was added, updating from v3.5.2 to v3.5.3. This reflects an updated revision of the document or system metadata.SummaryDifference0.0%

- Check13 days agoChange DetectedUpdated the Chile location text to use “Araucania” / “Temuco, Araucania, Chile” instead of “Región de la Araucanía” variants.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check41 days agoChange DetectedNaples, Italy, 80131 was added as a study location, replacing Napoli, Italy, 80131. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded updates to eligibility criteria, including prior PD-1/PD-L1/CTLA-4 exposure and prior MSD pembrolizumab participation. Expanded and clarified endpoint definitions (EFS, pathCR, OS) and adverse events across neoadjuvant/adjuvant cohorts, and updated study identifiers and revision metadata (EudraCT number, v3.4.3) with dates.SummaryDifference0.4%

- Check78 days agoChange DetectedGastric cancer is now listed as the study focus. The Resources section now includes the Genetic and Rare Diseases Information Center, and the page revision has been updated to v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.